DAX-0,57 % EUR/USD+0,23 % Gold+0,31 % Öl (Brent)+0,64 %

+++Unentdeckte Biotechperle+++Treatment of AIDS++++ - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

Hallo, heute stelle ich eine Unentdeckte Biotechperle
vor! Lest mal unten den Bericht! Von dieser Biotechfirma
ist denke ich großes zu erwarten! Bitte fragt nicht jeden Tag wann die Aktie explodiert. Ich sehe diese Aktie als langfristigeres Invest! Hier fehlt nur eine neue Meldung,
oder packt sie auf Eure Watchliste!! Bei GENR (Nasdaq) hatte ich das gleiche Gefühl und bin bei 0,3$ rein und bei 4$ raus. seht mal meinen Bericht vom letzten Jahr zu GENR.
Würde die Aktie nicht empfehlen, wenn ich nicht mich informiert hätte. Geht mal auf die Internetseite ...

http://www.adviral.com/ADVR/index.htm

WKN: 873511 ADVANCED VIRAL RESEARCH CORP. REGISTERED SHARES DL -,00001

Kurs: 0,126 $
Börse: OTC BB





ADVR`s AVR118 Granted a Patent in China for the Treatment of AIDS

PRNewswire-FirstCall via Comtex/ -- Advanced Viral Research Corp. (ADVR) today announced that China has recently granted the Company a patent for the treatment of AIDS patients with AVR118 (formerly known as Product R). The claims in the patent awarded by China cover the administration of AVR118 in combination with other anti-HIV drugs.

As previously reported, preliminary results from an Israeli clinical trial indicate that AVR118, a novel immunomodulator, may improve the quality of life of the patient, including increasing appetite, weight gain or stability and activities of daily living. AVR118 is also believed to be useful in enhancing the therapeutic effectiveness of the HAART drugs, as well as serving to mitigate the toxicity of HAART drugs.

The United Nations currently estimates that there are 1.5 million HIV carriers in China. New HIV infections in China have been increasing annually by about 30%. Chinese officials and the United Nations have warned that 10 million people could be infected by 2020.

"A recent United Nations Report on China found that the world is `witnessing the unfolding of an AIDS epidemic of proportions beyond belief`," said Eli Wilner, Chairman of the Board of ADVR. "The report went on to note that China is on the verge of a catastrophe that could result in unimaginable suffering, economic loss and social devastation."

"This patent not only further protects ADVR`s intellectual property in a potentially large market, but also serves as an additional opportunity for us to broaden the awareness of what ADVR is attempting to accomplish in this therapeutic category," noted James T. D`Olimpio M.D. "The announcement of this patent can assist us in educating the world`s researchers about ways to combat AIDS." Dr. D`Olimpio is a leading expert in oncology research and treatment who has focused on the areas of symptom control, palliative care, and cancer cachexia. Dr. D`Olimpio serves as a consultant to ADVR helping the Company to communicate the clinical results of AVR118 and speaking on issues related cachexia. He also serves on the Company`s Scientific Advisory Board.

ADVR recently announced the preliminary results of an Israeli clinical trial from the first fifteen cachectic (body wasting) AIDS patients treated with the novel immunomodulator AVR118. The results midway in this trial, first publicly announced on November 10, 2003, showed improvement in appetite, weight gain or stability, and enhanced quality of life in all patients. None of the 15 patients reported any significant side effects from AVR118 therapy.

"The enhancement of quality of life and the increase in activities of daily living observed in cachectic AIDS patients treated with AVR118 in the Phase I/II clinical trial in Israel carries the promise of returning AIDS patients to productive activity and relieve the economic burden imposed by this disease on the individual and society. If ultimately proven in further clinical trials, the value of AVR118 therapy in populations suffering with AIDS may be especially important in third world countries that are experiencing explosive growth, such as China," stated Shalom Z. Hirschman, M.D., Chief Scientist at ADVR and author of the patent.

ADVR`s AVR118 represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, AVR118 has been termed a "switch-type" immunomodulator. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.

For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients` lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
deswegen heisse ich auch Genaera (Nasdaq GENR)
weil ich die mal im Januar letzten Jahres gepostet habe. Mein erster Post hier bei wallstreetonline.de

WKN: 873511 ADVANCED VIRAL RESEARCH CORP. REGISTERED SHARES DL -,00001

könnte auf lange/ kurze Sicht ebenfalls ein Highflyer werden!!
Lege mir diese aktie mal auf seite.

wenn ich heute cesy ( 55 % plus) verkaufe hole ich mir welche

heute hole ich mir erst deine empfohlene advc

Na denn bin mal gespannt
:kiss:
WKN: 873511 ADVANCED VIRAL RESEARCH CORP. REGISTERED SHARES DL -,00001

@carlomaina, richtig , aus dem Gewinn von CESY in ADVC

Hallo zusammen, wer auf meine Empfehlungen IBZT, PACC, IVOC, CESY usw. gehört hat jetzt einiges verdient.Ich würde mich heute auf jeden Fall von CESY trennen, haut sie heute raus!! die hat ja gestern wieder 40% gemacht...Investiere in ADVC dieser Wert hat noch viel Potential nach oben!! gestern mit 17% plus geschlossen, aber heute geht denke ich die Party erst richtig los...

WKN: 923286 ADVANCED COMMUNICAT.TECH.INC. REGISTERED SHARES DL -,01





http://bigcharts.marketwatch.com/quickchart/quickchart.asp?s…

WKN: 923286 ADVANCED COMMUNICAT.TECH.INC. REGISTERED SHARES DL -,01

schaut euch den Umsatz von gestern an, wenn das nicht nach Ausbruch oder NEWS ausschaut!! Also wer noch keine hat, sollte sich dringend welche ins Depot legen. Ich denke heute sind wieder 20-40% drin, ist immer so bei diesen Werten.
ein paar Gründe warum die Party weitergeht!

1. Chartausbruch
2. die Aktie wird in den US-Boards heiss diskutiert
3. mein Bauchgefühl wie bei IBZT!!! mehrere 1000%
4. Handelvolumen ist so gestiegen, das die Amis kaufen müssen
5. meistens steigen OTC Werte, wenn immer 3 Tage hintereinander wie Cesy, PACC und ADVC hat erst +17%
6.kommende NEWS?
7.nachb;rslich im Plus
8.........könnte weiterschreiben

und den Gewinn dann in ADVR!!!!


Gruß
Genaera
nur das keine Mißverständnisse aufkommen
zu Punkt 3 der oberen Meldung

3. mein Bauchgefühl wie bei IBZT!!! mehrere 1000%

hat IBZT gemacht!!

und mein Gefühl sagt ADVC explodiert , nicht das sie
auch mehre 1000% machen, aber mehre 100% reichen ja auch :)
Hallo Genaera

Seit einiger Zeit lese ich deine Postings. Sie sind mit das gescheideste was man hier so sonst liest. Auch inhaltlich liegst du immer richtig. Aber das weißt du ja selbst.
Ich persöhnlich habe ein Problem mit den WKN nummern 873511 und 923286. Weder im W.O. noch in Finanztreff kann ich die Aktien mir anzeigen lassen.
Frage: Sind die Zahlen nicht richig oder werden die in DE nicht gehandelt?
Danke im für deine Mühe.
@RKLffm

danke für dein Vertrauen, muss dazusagen, alles was ich anpacke wird zu Geld. Gute Recherche wie bei VLGC (NASDAQ)
auch ne Biotechperle (AIDS Forschung) werd mich wohl trennen von ihr...



könnte dir jetzt noch 4-10 andere gute Beispiele nennen...
ob es Glück ist, ein bisserl gehört dazu, aber gute Recherche muss sein!!

Gruß
Genaera
YONKERS, N.Y., Jan 08, 2004 /PRNewswire-FirstCall via Comtex/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it has been awarded U.S. Patent Number 6.670,118 entitled "Method for Treating Papillomavirus Infections". The patent describes the use of AVR118 (previously known as Product R) for the topical treatment of patients suffering with lesions resulting from human papillomavirus (HPV) infections, including genital warts.

ADVR has completed a Phase I clinical trial in the U.S. to evaluate the safety of topical application of AVR118 in healthy volunteers. There were no local adverse reactions to the application of AVR118 to the skin of these subjects. The Company is now planning Phase II trials for the topical use of AVR118.

HPV is a common world-wide sexually transmitted infection (STI). The American Social Health Association estimates there are approximately 5.5 million new cases of sexually transmitted HPV infections reported each year and at least 20 million Americans are infected.

The most common clinical manifestation of HPV is warts which are benign tumors. The most common infections caused by strains of HPV are digital and plantar warts -- warts on the hands and feet, commonly seen in children. These warts represent one of the most prevalent dermatologic infections worldwide. Several strains of HPV are associated with the appearance of cervical cancer which is one of the most common malignancies infecting women. Some 500,000 cases of invasive cervical cancer are diagnosed worldwide each year. In developing nations, cervical cancer is the most common female malignancy, accounting for 24% of all cancers in women. In developed countries, cervical cancer ranks behind cancer of the breast, lung, uterus and ovaries, accounting for some 7% of all cancers in women.

Patients suffering with immunodeficiencies, such as patients with AIDS, are particularly susceptible to infection with HPV. Disseminated HPV in.fection is one of the opportunistic infections complicating AIDS and is manifested by eruption of generalized, often very painful warts over the body. At present, there is no specific and satisfactory therapy for disseminated HPV infection in AIDS patients.

"Use of AVR118 in the treatment of HPV infection is a potentially significant contribution of AVR118 to the therapy of a prevalent and troublesome viral infection that is responsible for much morbidity over the world. The potential of AVR118 as a therapy for disseminated HPV infection in patients with AIDS merits further clinical study," said James T. D`Olimpio M.D., a clinical consultant to ADVR.

ADVR`s AVR118 represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.

For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients` lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise
ADVR bewilligte VEREINIGTE STAATEN Patent für Behandlung der menschlichen Papillomavirus Infektion-E-mail oder druckt diese Geschichte Januar 8 2004, 07:31am UND YONKERS, N.Y., Jan. 8 /PRNewswire-FirstCall/ -- vorgerückte Viral Research Corp. (BB:ADVR) verkündeten heute, daß es VEREINIGTE STAATEN Patent die Nr. zugesprochen worden ist 6.670.118, die "Methode für das Behandeln der Papillomavirus Infektion" erlaubt wird. Das Patent beschreibt den Gebrauch AVR118 (vorher bekannt als Produkt R) für die aktuelle Behandlung der Patienten, die mit Verletzungen leiden, resultierend aus menschlicher papillomavirus (HPV) Infektion, einschließlich genitale Warzen. ADVR hat einen Phase I klinischen Versuch in den VEREINIGTEN STAATEN durchgeführt, um die Sicherheit der aktuellen Anwendung von AVR118 in den gesunden Freiwilligern auszuwerten. Es gab keine lokalen nachteiligen Reaktionen zur Anwendung von AVR118 zur Haut dieser Themen. Die Firma plant jetzt Phase II Versuche für den aktuellen Gebrauch AVR118. HPV ist eine allgemeine weltweite sexuell übertragene Infektion (STI). Die amerikanischen Sozialgesundheit Verbindung Schätzungen dort sind ungefähr 5.5 Million neue Fälle sexuell übertragener HPV Infektion, die jedes Jahr berichtet wird und mindestens werden 20 Million Amerikaner angesteckt. Die allgemeinste klinische Äusserung von HPV ist Warzen, die gutartige Tumoren sind. Die allgemeinste Infektion, die durch Belastungen von HPV verursacht wird, ist digitale und plantar Warzen -- Warzen auf den Händen und den Füßen, allgemein gesehen in Kinder. Diese Warzen stellen ein der überwiegendsten dermatologischen Infektion weltweit dar. Einige Belastungen von HPV sind mit dem Auftreten des zervikalen Krebses verbunden, der einer der allgemeinsten Malignancies ist, die Frauen anstecken. Ca. 500.000 Kästen des zervikalen Angriffskrebses werden weltweit jedes Jahr bestimmt. In sich entwickelnden Nationen ist zervikaler Krebs der allgemeinste weibliche Malignancy, Buchhaltung für 24% aller Krebse in den Frauen. In entwickelten Ländern ordnet zervikaler Krebs hinter Krebs der Brustes, des Lungenflügels, der Gebärmutter und der Eierstöcke, Buchhaltung für ca. 7% aller Krebse in den Frauen. Die Patienten, die mit Immunodeficiencies, wie Patienten mit AIDS leiden, sind gegen Infektion mit HPV besonders empfindlilch. Verbrittenes HPV in.fection ist eins der opportunistic Infektion, die AIDS erschwert und zeigt sich in Eruption der generalisierten, häufig sehr schmerzlichen Warzen über dem Körper. Zur Zeit, gibt es keine spezifische und zufriedenstellende Therapie für verbrittene HPV Infektion bei AIDS-Patienten.
#13:
Übersetzungstools sind einfach zum schreien:
" . . . Patent für Behandlung der menschlichen Papillomavirus Infektion-E-mail . . ."
So eine Infektion-E-mail ist schon was ansteckendes . . . :laugh:
Ich wollte eigentlich morgen einsteigen, aber ich denke man sollte eher heute rein.

oder was sagt ihr dazu:confused:
damit hab ich nicht gerechnet, aber hier die Hammernews!!

ADVR Granted U.S. Patent for Treatment of Human Papillomavirus Infections

THURSDAY , JANUARY 08, 2004 07:37 AM

YONKERS, N.Y., Jan 08, 2004 /PRNewswire-FirstCall via Comtex/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it has been awarded U.S. Patent Number 6.670,118 entitled "Method for Treating Papillomavirus Infections". The patent describes the use of AVR118 (previously known as Product R) for the topical treatment of patients suffering with lesions resulting from human papillomavirus (HPV) infections, including genital warts.

ADVR has completed a Phase I clinical trial in the U.S. to evaluate the safety of topical application of AVR118 in healthy volunteers. There were no local adverse reactions to the application of AVR118 to the skin of these subjects. The Company is now planning Phase II trials for the topical use of AVR118.

HPV is a common world-wide sexually transmitted infection (STI). The American Social Health Association estimates there are approximately 5.5 million new cases of sexually transmitted HPV infections reported each year and at least 20 million Americans are infected.

The most common clinical manifestation of HPV is warts which are benign tumors. The most common infections caused by strains of HPV are digital and plantar warts -- warts on the hands and feet, commonly seen in children. These warts represent one of the most prevalent dermatologic infections worldwide. Several strains of HPV are associated with the appearance of cervical cancer which is one of the most common malignancies infecting women. Some 500,000 cases of invasive cervical cancer are diagnosed worldwide each year. In developing nations, cervical cancer is the most common female malignancy, accounting for 24% of all cancers in women. In developed countries, cervical cancer ranks behind cancer of the breast, lung, uterus and ovaries, accounting for some 7% of all cancers in women.

Patients suffering with immunodeficiencies, such as patients with AIDS, are particularly susceptible to infection with HPV. Disseminated HPV in.fection is one of the opportunistic infections complicating AIDS and is manifested by eruption of generalized, often very painful warts over the body. At present, there is no specific and satisfactory therapy for disseminated HPV infection in AIDS patients.

"Use of AVR118 in the treatment of HPV infection is a potentially significant contribution of AVR118 to the therapy of a prevalent and troublesome viral infection that is responsible for much morbidity over the world. The potential of AVR118 as a therapy for disseminated HPV infection in patients with AIDS merits further clinical study," said James T. D`Olimpio M.D., a clinical consultant to ADVR.

ADVR`s AVR118 represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.

For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients` lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.



Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802


SOURCE Advanced Viral Research Corp.


CONTACT: Ronnie Welch, or Kelly Cinelli, +1-508-222-4802, both of CWR &
Partners, for Advanced Viral Research Corp.
/Company News On-Call: http://www.prnewswire.com/comp/903002.html" target="_blank" rel="nofollow">http://www.prnewswire.com/comp/903002.html

URL: http://www.prnewswire.com
http://www.adviral.com



Copyright (C) 2004 PR Newswire. All rights reserved.


-0-


KEYWORD: New York
INDUSTRY KEYWORD: HEA
MTC
BIO
OTC


STOCK SYMBOLS: [(advr)]
Hallo, ich denke heute gehts weiter!
Vorbörslich im Plus!
erstes Kursziel 0,5$ :)
so nachdem sie die letzte zeit zwischen 0,13-0,15$ rumgedümpelt ist, gab´s heute ein ordentliches plus von 18,52% bei hohem volumen. :eek:

so wie ich das sehe gab´s aber keine news?! bin mal gespannt wie´s montag weiter geht.
sehr schön es geht weiter....momentan bei 0,175$!! :eek:
mit ein wenig glück könnten heute die 0,20 getestet werden...
der vogelgrippe sei dank(?) geht´s heute erneut nach norden. außerdem wurde advr heute in der rubrik "Special Stocks to Watch!" der market news des otc bulletin boards genannt.
ok, zugegeben sind das wohl nur kurzfristige einflüße...aber werft vielleicht mal ein blick auf den chart!

good trades!
ADVR: Presents Positive Study Data re AVR118 for Cancer

FRIDAY , FEBRUARY 20, 2004 08:32 AM

Advanced Viral Research Corp. (ADVR) presented preclinical data on its flagship product, AVR118, at the 1st International Society of Chemotherapy conference in Florence, Italy. The objectives of the studies were to determine the in vitro biologic effects of AVR118 in two separate experimental cancer systems: 1) a differentiation model (leukemia cells) and 2) a metastasis model (invasive breast cancer cells). The presentation showed that AVR118 exhibits two distinct anti-cancer effects in its ability to induce maturation of malignant leukemic cells, and in its ability to inhibit metastasis and invasion of a highly malignant breast cancer cell line.


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.